The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Understanding dynamic therapeutic responses with single-cell RNA-sequencing
Curtis Perry, MD, PhD, Yale University, New Haven, CT, comments on the value of perturbational single-cell RNA-seq in modeling therapeutic responses in Merkel cell carcinoma (MCC) and small cell lung cancer (SCLC) tumors, highlighting its ability to capture dynamic responses and identify checkpoints that can be reactivated. Dr Perry emphasizes the need to assess individual patient responses to therapy, rather than relying on static signatures, to determine the effectiveness of treatment and identify opportunities for reactivation. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
That’s a really great question and a really fundamental one in immunology because often in immunology, whenever we activate something, we also set up the same processes to turn off that signal or inactivate. So a lot of the checkpoints that we’re actually treating therapeutically are those different mechanisms to suppress responses. So what we need to do is to figure out if particular patient samples are still responsive to a therapy, and if not, how do we unleash that therapy again...
That’s a really great question and a really fundamental one in immunology because often in immunology, whenever we activate something, we also set up the same processes to turn off that signal or inactivate. So a lot of the checkpoints that we’re actually treating therapeutically are those different mechanisms to suppress responses. So what we need to do is to figure out if particular patient samples are still responsive to a therapy, and if not, how do we unleash that therapy again. That really is a dynamic response, and so that’s really what we’re looking at, rather than a signature response, we want to see the response itself.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Research Funding – AstraZeneca (Inst)
